<DOC>
	<DOCNO>NCT02151344</DOCNO>
	<brief_summary>H7N9 virus cause recent outbreak severe illness human China . The purpose study evaluate safety immune response H7N9 A/Anhui/13 ca influenza virus vaccine follow inactivated subvirion H7N9 vaccine vary interval .</brief_summary>
	<brief_title>Evaluating Safety Immune Response Live H7N9 Influenza Virus Vaccine Followed Inactivated H7N9 Influenza Virus Vaccine , Given Varying Intervals</brief_title>
	<detailed_description>H7N9 avian influenza ( AI ) viruses responsible recent outbreak illness human China , associate severe respiratory illness result acute respiratory distress syndrome ( ARDS ) intensive care unit ( ICU ) admission . The purpose study evaluate safety , infectivity , immunogenicity live attenuate H7N9 A/Anhui/13 cold adapt ( ca ) influenza virus vaccine follow boost inactivate subvirion H7N9 vaccine vary interval . This study enroll participant five cohort . Participants Cohorts 1 , 2 , 3 , 4 admit isolation unit Study Day -2 . On Study Day 0 , participant receive one dose H7N9 A/Anhui/13 ca influenza virus vaccine via nose spray device . While isolation unit , participant undergo physical examination nasal wash day , blood collection select day . Participants remain isolation unit least 9 day receive vaccine , possibly longer , depend test result . Participants Cohorts 1 2 return isolation unit 4 8 week receive first vaccine ( approximately Day 28 ) . They receive second dose H7N9 A/Anhui/13 ca influenza virus vaccine repeat procedure occur first vaccination . Participants receive one dose inactivate subvirion H7N9 vaccine 1 month ( Cohort 1 ) 2 month ( Cohort 2 ) receive second vaccine . Participants Cohorts 3 4 receive inactivate subvirion H7N9 vaccine either 1 month ( Cohort 4 ) 2 month ( Cohort 3 ) receive one dose live attenuate vaccine . For Cohorts 1-4 , participant study visit occur 7 , 14 , 28 , 90 day receive vaccine include medical history review , physical examination , blood collection select visit . Participants Cohort 5 receive one dose inactivate subvirion H7N9 vaccine Day 0 one dose Day 28 . Study visit occur Days 0 , 7 , 28 , 35 , 42 , 56 , 118 , include blood collection physical examination . Participants Cohort 5 admit isolation unit .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant female 18 year 49 year age , inclusive . Children recruit enrol study apparent risk group , safety consideration , need isolation . General good health , without significant medical illness , physical examination finding , significant laboratory abnormality determine investigator Agree storage blood specimens future research Available duration trial Willingness participate study evidence sign informed consent document Female participant childbearing potential must agree use effective birth control method duration study ( example , pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; intrauterine device ; abstinence heterosexual intercourse ; surgical sterilization ) . All female participant consider childbearing potential except undergone hysterectomy menopause occur least 1 year prior study . Pregnancy , determine positive human choriogonadotropin ( betaHCG ) test Currently breastfeed Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study include urine test Behavioral cognitive impairment psychiatric disease opinion investigator affect ability participant understand cooperate study protocol Previous enrollment H7 influenza vaccine trial study avian influenza vaccine Seropositive H7N9 influenza A virus ( serum HAI titer great 1:8 ) Positive urine drug toxicology test indicate narcotic use/dependency Have medical , occupational , family problem result alcohol illicit drug use past 12 month Other condition opinion investigator would jeopardize safety right participant trial would render participant unable comply protocol History anaphylaxis Allergy oseltamivir determine participant report Current diagnosis asthma reactive airway disease ( within past 2 year ) History GuillainBarr√© Syndrome Positive enzymelinked immunosorbent assay ( ELISA ) confirmatory test ( e.g. , Western blot HIV1/HIV2 differentiation assay ) human immunodeficiency virus1 ( HIV1 ) Positive ELISA confirmatory test ( e.g. , recombinant immunoblot assay ) hepatitis C virus ( HCV ) Positive hepatitis B virus surface antigen ( HBsAg ) ELISA Known immunodeficiency syndrome Use corticosteroid ( exclude topical preparation ) immunosuppressive drug within 30 day prior vaccination Receipt live vaccine within 4 week kill vaccine within 2 week prior study vaccination History asplenia Body mass index ( BMI ) great 40 Receipt blood bloodderived product ( include immunoglobulin ) within 6 month prior study vaccination Current smoker unwilling stop smoking duration study . More information criterion available protocol . Travel Southern Hemisphere within 14 day prior study vaccination Travel cruise ship within 14 day prior study vaccination Receipt another investigational vaccine drug within 30 day prior study vaccination History hypersensitivity component investigational product include egg egg protein , serious , life threatening , severe reaction previous influenza vaccination Individuals use intranasal medication chronically Receipt antiviral therapy antiviral agent within 48 hour prior receipt investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>